The market’s harsh reaction to the Q4 miss seems unreasonable
08/02/24 -"Even though Q4 profitability fell short of the street’s expectations, the 2023 results met the management’s CER guidance. The management’s 2024 outlook was healthy as well. Still, the share price ..."
Pages
65
Language
English
Published on
08/02/24
You may also be interested by these reports :
19/12/25
The change in the target price is due to a change in the analyst covering the stock, complemented by the usage of systematic intrinsic and peer-based ...
17/12/25
Since Bayer’s shares have already surged 87% ytd, recovering to their highest levels in the last two years, we do not foresee a material upside ...
12/12/25
Eli Lilly’s Retatrutide grabbed headlines with c.29% weight-loss efficacy in late-stage trials for obese patients who also had knee osteoarthritis. ...
08/12/25
Despite US tariff threats, drug pricing pressures and the persistent insistence from the US government to reshore manufacturing, the AV Big Pharmas ...